256519-10-5 Usage
Uses
Used in Pharmaceutical Research:
2H-Benzimidazol-2-one,4-fluoro-1,3-dihydro-(9CI) is used as a research compound for exploring its potential biological activity and applications in drug discovery. Its unique structure, including the benzimidazole ring and fluorine substituent, makes it an interesting candidate for further study in medicinal chemistry.
Due to the limited information provided on the specific applications of 2H-Benzimidazol-2-one,4-fluoro-1,3-dihydro-(9CI), it is not possible to list specific application types and reasons for its use in different industries. However, its potential in pharmaceutical research suggests that it may be utilized in the development of new drugs or therapies targeting various diseases or conditions. Further research and documentation would be required to provide a more detailed account of its uses.
Check Digit Verification of cas no
The CAS Registry Mumber 256519-10-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,6,5,1 and 9 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 256519-10:
(8*2)+(7*5)+(6*6)+(5*5)+(4*1)+(3*9)+(2*1)+(1*0)=145
145 % 10 = 5
So 256519-10-5 is a valid CAS Registry Number.
256519-10-5Relevant academic research and scientific papers
Renin inhibitors
-
Page/Page column 481-482, (2012/03/27)
The invention relates to compounds having the formulae: wherein the variables are as defined herein. The invention further relates to methods of making and using these compounds, and pharmaceutical compositions, kits and articles of manufacture comprise the compounds.
CHEMICAL COMPOUNDS
-
Page/Page column 31, (2012/01/03)
There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
FKBP inhibitors
-
, (2008/06/13)
Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.
